Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

n the United States. Imiquimod and other TLR7 agonists have also demonstrated early clinical activity against other tumor types, including melanoma and chronic lymphocytic leukemia.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the planned scope and trial design of the ANA773 clinical trial, the belief that ANA773 holds promise for the treatment of a range of malignancies, and that it may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy, Anadys' ability to identify a dose and schedule for Phase II investigation by the end of this year and the ability to develop ANA773 as a therapy for patients with cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, di
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
(Date:5/17/2013)... 17, 2013 Dr. Sparano is Professor ... Health at the Albert Einstein College of Medicine and ... Montefiore Medical Center. He is also Associate Director ... leads the Einstein Breast Cancer Working Group, a multidisciplinary ... cancer research. He also serves as Vice Chair of ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Oven Industries ... capabilities. The 5R6-900 temperature controller has many user-friendly benefits. ... plugged into the wall as a self-contained temperature ... This distinctive detail makes the device unique, as well ... controller can also be used universally, which allows the ...
(Date:5/17/2013)... recipient,s immune system identifies the transplanted organ as foreign ... T cells, the immune cells that mediate rejection, must ... order to migrate to the transplanted organ. In this ... Fadi Lakkis and colleagues at the University of Pittsburgh ... cells is not required for migration. Instead, these cells ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3New Temperature Control Products Announced by Oven Industries Inc. 2
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Officer of Alexion,Pharmaceuticals, will present at the William ... 9:10 a.m., local time (10:10 a.m., eastern) on,Thursday, ... Mr. Sinha,s remarks will be available live. You ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical tests,announces upcoming company presentations ... (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ... July 25, 2008., -- July 28 - ...
... Universities of Cambridge and Bristol have revealed that the ... the vacuum of a mass spectrometer. Their research ... Express . , The researchers were surprised to discover ... always been assumed that they would not survive once ...
Cached Biology Technology:Upcoming Beckman Coulter Investor Events Second Half of 2008 2Membrane complexes take flight 2
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
(Date:5/18/2013)... 2013) Research presented at Digestive Disease Week ... through diet and lifestyle. , Individuals suffering ... muscle strength, fatigue and poor quality of life. ... in remission. A randomized, double blind, placebo-controlled study ... supplementation corresponded to significant relief of these symptoms. ...
(Date:5/18/2013)... 18, 2013) An increasing number of U.S. ... to resolve, according to research presented at Digestive ... targeting obesity, researchers at the Cleveland Clinic Children,s ... pattern of exhaled breath compared to their lean ... compound levels that can be correlated to potential ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... A global collaborative has produced a first draft ... that will lead to insights in agriculture, medicine, conservation ... farm at the University of Illinois will now be ... had their genomes sequenced. Researchers will announce the achievement ...
... / - PDC Biotech GmbH (PDC) today announced the ... Verwaltungs AG (Munich) and Edmond de Rothschild Investment Partners (Paris) co-led ... used to complete preclinical work and the first clinical study of ... for the treatment of preterm labour and primary dysmenorrhea . ...
... 2009) -- A husband and wife team of American paleontologists has ... ago during the early Cretaceous of central Montana. The new ... of the Canadian Journal of Earth Sciences . Ankylosaurs are ... a plate-like armour with two sets of sharp spikes on each ...
Cached Biology News:First draft of the pig: Researchers sequence swine genome 2First draft of the pig: Researchers sequence swine genome 3PDC Biotech GmbH Announces Close of Series A Financing 2PDC Biotech GmbH Announces Close of Series A Financing 3New dinosaur species from Montana 2
TXNL2 Antibody...
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
ATGL Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: